The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
pl75 takes the **** out of himself constantly… bitter and grumpy know it all, ok for him and his clique to post about pitch forks and rant, however when it’s someone else it’s all bs and look at my green box list, like anyone gives a flying f**k about that. hypocrite to the max. toaster and a bath ffs pathetic loser.
Let’s see what happens to the share price when a deal does arrive. Truthfully I hope you miss out with the amount of time you spend here not invested. 👍😊 The short term share price has no impact whatsoever on longterm success. You assume because the price is currently low the company is failing, sorry to give you a lesson in investing 101 however they are not linked. Why will this fail the FDA trials again scientifically??? You never answer that question because it doesn’t suit your agenda here. Would say good luck however you actually need to be invested in the first place.
That’s the problem. 90% of people invested in Avacta don’t actually know anything about the company or its potential they want everything now and don’t have the patience to see through the necessary approvals. You either have faith the company will pass the trials and get FDA approval or you don’t. As a LTH you can take advantage of these prices and sentiment to get average down in the knowledge the platform works as intended and is only a matter of time. The risk in Avacta was always the science completely failing which doesn’t look likely considering they are going all in on TX!! Alternatively you can sell up and join the next hot stock. Simple enough choice.
You think they want to keep this short open moving into the second half of the year. Windy why would DB a prestigious institution be concerned with a pharmaceutical company on AIM 🤔🤔 use your brain 🧠. The founder of GSA has direct ties with the company, former employee etc. the volumes are only going to dry up further as the last of the placing shares moves into LTH’s hands. I would have tried to close just after the BC was announced. Imo let’s see what happens in a few weeks time when the squeeze happens. The CEO will want to make a statement of intent quickly, they always do when new to the job.
Resorting to dirty tactics, to try drive the price down imo. Looks like GSA have a relationship with DB, who put out this 40p target, this is desperate stuff. The volumes have completely dried up. They obviously overestimated what the bond conversion would do to the share price and missed the target. SMDC were also expected to review the data end of April so results could easily be released next week after the bank holiday. With the new CEO in place also probably wanting to make an impression and statement of intent quickly. (We could easily see some signed deals to get the ball rolling) The longer this short goes on the potential for failure gets way higher 🔥🔥. I think they have missed the opportunity window myself to close out when sentiment was an all time low.
What’s more surprising is folks don’t even look at a mkt cap and spout random BS figures like £30-40 or 10-20p not knowing what that value actually equates to as they think the share price is the value not understanding the significance of it.
🤣🤣 🥱Was using yahoo for calculations and assumed it just converted for us audience as no currency, double checked value on London Stock Exchange seen it was GBP. Was genuine error which I spotted straight away. Long day 🤣🤣
Potentially a 1.75bn deal for preclinical. Would expect more here tbh based on the data. See what happens, if BP were negotiating with Avacta on a take-over deal, the placing would make sense as that would protect negotiating strength money in the bank. Up your offer or we have the capability to go solo phase 2 and do license deals. Nothing off the table suggests this scenario does have some merit however that’s just pure speculation on my part. Very interesting though 🤔🤔💯
Probably more the fact the Dox sensitive tumours is in the high FAP category and they would guarantee a response from the platform cleaving and dumping the warhead. You wouldn’t want to take any chances, with using mid or low fap tumours just incase you get inferior results. If they design other warheads to target mid fap tumours that are sensitive to that warhead happy days.
Some tumours are unfortunately not Dox sensitive, a response wouldn’t have been expected in these Tumours. Good thing is moving forward the trials will be built around high fap dox sensitive tumours, that they would expect a response from (STS is one example). Everything will be designed for success moving forward as they have proven safety so can now target tumours that AVA6000 was designed for in the first place to prove efficacy which is a formality imo.
Stop changing the subject to confuse things with an old timeline that got adjusted with an RNS. Until we are told otherwise we are on track as per the presentation and the RNS, clear as day and not confusing at all. Unsure why you are still here if you don’t believe what the company tells you in official communication correspondence. Do you have a hero complex as well? You are not even invested haha pathetic loser. 🤣🤣🤣